Celyad Oncology SA

As of December 31, 2025, Celyad Oncology SA carries a market capitalization of 6.70M, placing it among publicly traded companies globally. Its enterprise value stands at 4.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Celyad Oncology SA's next confirmed earnings release is scheduled for March 25, 2027.

As of December 31, 2025, Celyad Oncology SA has 44.76M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Celyad Oncology SA maintains a current ratio of 1.92, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on August 7, 2026, Celyad Oncology SA's stock has declined approximately 47.17% over the past 52 weeks.

As of December 31, 2025, Celyad Oncology SA holds 2.01M in cash and equivalents against - - in total debt, resulting in a net debt position of -2.01M. Total book value stands at 2.86M, with working capital of 1.97M providing operational flexibility.